In this article, we will discuss Ramucirumab (28). So, let’s get started.
The safety and effectiveness of Ramucirumab in pediatric patients have not been established. In animal studies, effects on epiphyseal growth plates were identified. In cynomolgus monkeys, anatomical pathology revealed adverse effects on the epiphyseal growth plate (thickening and osteochondropathy) at all doses tested (5-50 mg/kg).
Ramucirumab exposure at the lowest weekly dose tested in the cynomolgus monkey was 0.2 times the exposure in
humans at the recommended dose of ramucirumab as a single agent.